Brief: Chinook Therapeutics Announces First Patient Enrolled In Pivotal Phase 3 Align Study Of Atrasentan
16/03/2021 13:03
March 16 (Reuters) - Chinook Therapeutics Inc KDNY.O :
* CHINOOK THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN
PIVOTAL
PHASE 3 ALIGN STUDY OF ATRASENTAN FOR PATIENTS WITH IGA
NEPHROPATHY
* CHINOOK THERAPEUTICS - PHASE 2 AFFINITY TRIAL OF
ATRASENTAN FOR
PATIENTS WITH GLOMERULAR DISEASES ALSO ON TRACK TO BEGIN
ENROLLMENT IN H1 OF 2021
Source text for Eikon: ID:nGNX65JC66
Further company coverage: KDNY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chinook Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Chinook Therapeutics
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
Brief: Muddy Waters- Remains Short On Chinook Therapeutics Inc